Drug Database
AD

adalimumab (Mabura)

✓ Approved

Hetero Labs · TNF · Monoclonal Antibodies

What is adalimumab?

adalimumab is a monoclonal antibodies developed by Hetero Labs. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesMabura
CompanyHetero Labs
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetTNF
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Hetero Labs

Mechanism of Action

Molecular Targets

adalimumab acts on 1 molecular target:

TNFtumor necrosis factor (TNFA, TNF-alpha)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

adalimumab is developed for 10 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersHidradenitis✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

+5 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedBMC gastroenterology2026-09-19

Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients.

Amer Ibrahiem I, El Batae Hassan H, Elshaer Yasmine A YA, Sherief Dalia Elsayed DE et al.

Anti-tumor necrosis factor-α (anti-TNF-α) agents are a cornerstone in inflammatory bowel disease (IBD) therapy, yet primary non-response remains a significant practical challenge. Leucine-rich alpha-2 glycoprotein (LRG) has been recognized as a promising marker for disease activity. This study aimed to evaluate the predictive significance of pre-treatment serum LRG for response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients. In this prospective cohort study, 100 biologic-naïve IBD adult patients (50 Crohn's disease [CD], 50 ulcerative colitis [UC]) and 100 healthy controls were enrolled. Patients received induction therapy with adalimumab or infliximab. Clinical, biochemical, and endoscopic evaluations were conducted at baseline and at week 24. Response was defined by clinical indices and endoscopic improvement, while biochemical normalization was evaluated as a secondary, supportive parameter. IBD patients had significantly elevated baseline LRG levels compared to the healthy controls (p < 0.001). Responders' baseline LRG was substantially lower than that of non-responders in both UC (26.53 vs. 34.88 µg/mL; p = 0.008) and CD (26.03 vs. 35.07 µg/mL; p = 0.006). Receiver operating characteristic analysis revealed a cut-off of > 29 µg/mL for predicting non-response, yielding sensitivities of 74.2% and 80.0% with specificities of 69.57% and 65.71% for UC and CD, respectively and negative predictive values of 85.7% for UC and 88.5% for CD. Multivariate regression confirmed baseline LRG as an independent predictor of non-response. Baseline serum LRG levels > 29 µg/mL demonstrated moderate discriminatory ability for predicting primary non-response to anti-TNF-α therapy in Egyptian IBD patients. LRG may serve as a useful adjunctive biomarker for pre-treatment risk estimation and recognizing patients who may require alternative therapeutic strategies.

PMID 42760552
Read full article →
PubMedJournal of investigative medicine high impact case reports2026-09-18

Legionella Myocarditis with Reversible Left Ventricular Dysfunction in a Patient Receiving Adalimumab: A Case Report.

Alzubi Alhasan Saleh AS, Shelig Mohamed M, Hegazy Yasser Y, Alagha Zakaria Z et al.

Legionella pneumophila is a well-recognized cause of community-acquired pneumonia, but its capacity to cause extrapulmonary complications, including myocarditis, remains underappreciated. Myocarditis is among the rarest and most serious cardiac manifestations of Legionella infection and may be underdiagnosed in critically ill patients, where troponin elevations are often attributed to sepsis-related myocardial injury. We report the case of a 51-year-old woman with diabetes mellitus, ulcerative colitis managed with adalimumab (a tumor necrosis factor-α inhibitor), and a significant smoking history who presented to the emergency department after being found unresponsive. She was febrile, tachycardic, and in respiratory distress, with laboratory findings significant for markedly elevated troponin (7,377 ng/L), creatine kinase (10,561 U/L), and procalcitonin (27 ng/mL). Echocardiography revealed severe left ventricular systolic dysfunction with an ejection fraction of less than 15%. A urine antigen test confirmed Legionella pneumonia. Hemodynamic assessment using the Fick method excluded cardiogenic shock, and left heart catheterization demonstrated no obstructive coronary artery disease. Following a 14-day course of levofloxacin along with supportive care, her cardiac function recovered completely, with a follow-up ejection fraction of 71%. This case highlights the potential for Legionella infection to cause fulminant yet fully reversible myocarditis and underscores the role of TNF-α inhibitor therapy as a predisposing factor for severe Legionella disease. Clinicians should maintain a high index of suspicion for myocarditis in patients with Legionella pneumonia who present with unexplained troponin elevation and new systolic dysfunction, as early recognition and targeted antimicrobial therapy can lead to complete cardiac recovery.

PMID 42758908
Read full article →
PubMedDermatology (Basel, Switzerland)2026-09-18

Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study.

du Yanyu Y, Zhan Jipang J, He Renliang R, Zhang Lian L

Biologic therapies have transformed the management of moderate-to-severe hidradenitis suppurativa (HS). However, real-world comparative data between tumor necrosis factor-alpha (TNF-α) inhibitors and interleukin-17 (IL-17) inhibitors in Chinese populations remain limited. To compare the short- and mid-term effectiveness and safety of TNF-α versus IL-17 inhibitors in adult Chinese patients with HS. This single-center retrospective cohort study included adult patients (≥18 years) with moderate-to-severe HS treated with biologics. Patients were stratified into TNF-α inhibitor and IL-17 inhibitor groups. The primary endpoint was achievement of Hidradenitis Suppurativa Clinical Response (HiSCR50) at week 16. Secondary endpoints included HiSCR50 at weeks 12, and safety outcomes. A total of 79 adult patients were included (TNF-α: n=25; IL-17: n=54). At week 12, response rates remained similar (72.0% vs. 63.0%). By week 16, a decline in response was observed in the TNF-α group (56.0%), whereas the IL-17 group maintained a stable response (66.7%). Safety profiles were acceptable in both groups, with one discontinuation due to fungal infection in the IL-17 group. Both TNF-α and IL-17 inhibitors demonstrate rapid onset of action in HS. However, IL-17 inhibitors may offer superior mid-term durability of response, supporting their role as a preferred option for sustained disease control.

PMID 42758664
Read full article →
PubMedOcular immunology and inflammation2026-09-18

Biologic Therapy in Refractory Non-Infectious Uveitis: An Analysis of 60 Cases at a Tertiary Eye Care Centre from South India.

Agrawal Mohini M, Raghu Keerthana K, Kaushik Viswanath V VV, Vashisht Prashant P et al.

To evaluate the effectiveness and safety of biologic therapy in patients with refractory non-infectious uveitis (NIU) in a real-world clinical setting. A retrospective observational study was conducted at a tertiary eye care centre in South India between 2022 and 2025. Patients diagnosed with NIU, who were not responding to conventional treatment and had received biologics during this period, were included. Demographic details, anatomical classification, etiological diagnosis, type of biologic used, treatment duration, clinical outcomes, and adverse events were analysed. A total of 60 patients with refractory NIU receiving biologic therapy were included. The mean age at biologic initiation was 23.1 ± 13.7 years, comprising 27 (45%) paediatric and 33 (55%) adults. The mean duration of uveitis prior to biologic initiation was 34.48 ± 52.36 months. Anterior uveitis was the most common (40%). Autoimmune etiologies predominated, with juvenile idiopathic arthritis-associated uveitis (28.3%), HLA-B27-associated uveitis (23.3%), and Behçet disease (20%). Adalimumab was the most frequently used biologic agent (88.3%) followed by Infliximab (5%), golimumab (3.3%) and tocilizumab (3.3%). Biologic therapy resulted in significant control of intraocular inflammation (p < 0.0001). Visual acuity remained stable throughout the follow-up. Treatment modification was required in 7 patients (11.7%). Side effects were observed in 3 (5%) patients, 2 (3.3%) showed inadequate response and 2 patients (3.3%) discontinued biologics due to financial constraints. Biologic therapy is an effective and safe therapy for refractory non-infectious uveitis across all age-groups and etiologies. Early escalation to biologics may help arrest long-term cumulative inflammatory damage and preserve visual function by sustained inflammatory control.

PMID 42755380
Read full article →
PubMedJournal of pharmaceutical and biomedical analysis2026-09-18

Development and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes.

Aibara Nozomi N, Yamazawa Ryuji R, Matsugi Yuya Y, Kutsuna Yuki Jimbayashi YJ et al.

Identification of antibody-binding epitopes on antigens is essential for understanding the pathogenic roles of immune complexes (ICs) in autoimmune diseases and for the development of diagnostics and therapeutics. However, methods for direct epitope characterization of IC-antigens formed in vivo remain limited. Here, we investigated antibody framework region (FR)-targeted cross-linking mass spectrometry (XL-MS) as an approach to identify epitopes in patient-derived ICs. Four IC models with known epitopes (tumor necrosis factor alpha-adalimumab, tumor necrosis factor alpha-infliximab, human epidermal growth factor receptor 2-pertuzumab, and human epidermal growth factor receptor 2-trastuzumab) were analyzed using three cross-linkers of different lengths: bis(sulfosuccinimidyl) suberate (BS3), bis(sulfosuccinimidyl) glutarate (BS2G), and 1,1'-carbonyldiimidazole (CDI). BS3 preferentially generated antigen-FR cross-links, whereas CDI predominantly produced antigen-complementarity-determining region cross-links. Several cross-linked peptides contained antigen sequences overlapping previously reported epitopes, supporting the validity of this approach for epitope mapping. As a proof-of-concept clinical application, serum samples from patients with primary biliary cholangitis were analyzed using a targeted database containing four disease-associated autoantigens (PDC-E2, BCOADC-E2, OGDC-E2, and E3BP). Two candidate epitope peptides were identified. One corresponded to a known immunodominant epitope, whereas the other represented a novel candidate site supported by computational epitope prediction analysis. These findings demonstrate that FR-targeted XL-MS provides a strategy for identifying epitopes within patient-derived IC-antigens through the use of conserved antibody FRs. This approach may contribute to understanding antigen recognition mechanisms in autoimmune diseases and support the discovery of disease-relevant therapeutic targets.

PMID 42759225
Read full article →
PubMedOcular immunology and inflammation2026-09-17

Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea.

Choi Seung Woo SW, Ryu Eun Jeen EJ, Woo Se Joon SJ

This post-marketing surveillance study reports the real-world safety and effectiveness of adalimumab (Humira®, AbbVie Inc.) among patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) in Korea. The study was conducted at 17 medical centres from January 2018 to July 2020. Safety (155 patients) was analysed by collecting adverse events (AEs) and adverse drug reactions (ADRs) data. Effectiveness assessments (148 patients) included anterior chamber cell grade, vitreous haze grade, and best corrected visual acuity (BCVA) change. At baseline, the mean duration of uveitis was 3.9 ± 4.0 years (n = 101) and the mean number of relapses in the past year was 2.5 (n = 52). The most common anatomical uveitis phenotype was panuveitis (n = 110, 71.0%). One patient received prior infliximab; within the previous 3 months, 75.4% and 93.3% of patients received glucocorticoids and immunosuppressants, respectively. The mean daily corticosteroid dose decreased from 9.7 ± 7.8 mg at the start of the study to 6.6 ± 6.0 mg at the end of the study (p < 0.0001). AEs and ADRs were reported in 13 patients (8.4%, 1.9% serious) and 5 patients (3.2%), respectively. The most common ADR was injection-site discomfort. Twenty-nine patients (18.7%) discontinued adalimumab within 6 months; 34 patients discontinued during follow-up, most commonly for cost issues (64.7%). Three patients discontinued adalimumab due to AEs. Regarding effectiveness, from baseline to 22 weeks, anterior chamber inflammation and vitreous haze tended to improve significantly; there was no BCVA worsening. In the real-world setting, adalimumab treatment showed an acceptable safety profile, with serious AEs reported in three patients but no serious ADRs related to adalimumab, and demonstrated potential effectiveness in Korean patients with NIIPPU.

PMID 42752274
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about adalimumab